SMB·BIO

'No alternative, yet more restrictions': Choline alfoscerate curbs push MCI patients toward unverified supplements

by
Choi Eun-ji
Published : Nov. 20, 2026 - 09:04:08
    • Copy Completed!

View Korean Original

Clinical re-evaluation of choline alfoscerate shows clear improvement in patients with high medication adherence

48-week observation period seen as too short; large cohort study of 510,000 finds reduced dementia conversion risk

'Health supplements are food, not medicine — patients must see a specialist,' neurologist warns

Interview with Lee Sang-heon, professor at Korea University Ansan Hospital

Lee Sang-heon, a neurology professor at Korea University Ansan Hospital, speaks during an interview on Nov. 11.
Lee Sang-heon, a neurology professor at Korea University Ansan Hospital, speaks during an interview on Nov. 11.

"Mild cognitive impairment — the stage just before dementia — is a 'window of opportunity' that can improve with early detection and management. But with no adequate alternative drugs available, and choline alfoscerate, the leading treatment, now harder to access due to selective benefit restrictions, patients are turning to unverified health supplements."

이상헌 고대안산병원 신경과 교수

Lee Sang-heon, a neurology professor at Korea University Ansan Hospital, shared his medical assessment of the confusion in clinical settings and the results of the choline alfoscerate re-evaluation during an interview on Nov. 11.

Lee, a specialist in stroke and vascular cognitive impairment, warned that the treatment gap for mild cognitive impairment patients in South Korea could ultimately translate into a massive social cost — a rising rate of dementia conversion.

'MCI is not simple forgetfulness — it's a correctable golden window'

Mild cognitive impairment (MCI) refers to a state in which cognitive function falls below what is expected for a person's age and education level, while independence in daily life is still maintained. Unlike ordinary forgetfulness, which is a normal part of aging, MCI arises from abnormal pathological causes and carries a significant risk of progressing to dementia if left unmanaged.

"Not all MCI cases progress to dementia — if correctable causes are identified and managed, the condition can stabilize or even improve," Lee said. "Beyond degenerative factors, vascular changes, sleep disorders, depression and medications can all interact, which is why early comprehensive assessment and ongoing follow-up are essential."

Non-pharmacological management in daily life is equally important. "Patients need to be aware of their own cognitive decline and, rather than passively watching television, should engage in conversation and practice repeated learning — actively trying to understand and remember things," Lee said. "That kind of effort amplifies the effect of drug treatment."

'48-week trial too short — but protocol-adherent group shows meaningful results'

On the recently released results of the choline alfoscerate clinical re-evaluation for MCI patients, Lee said the study design and the nature of the disease must be examined carefully before drawing conclusions from the numbers alone.

The trial enrolled 852 patients — 426 with degenerative MCI and 426 with vascular MCI — and ran for 48 weeks. The primary endpoint in the full analysis set did not reach statistical significance.

However, in a pooled secondary analysis of the per-protocol set, patients who received choline alfoscerate showed a cognitive maintenance or improvement rate of 67.83 percent at 48 weeks, compared with 60.07 percent in the placebo group — a statistically significant difference of 7.76 percentage points.

"Cognitive assessments are prone to a learning effect from repeated testing, which tends to lift placebo group scores as well," Lee said. "Existing tools such as ADAS-Cog and MMSE also have limitations in capturing subtle early changes. On top of that, MCI patients have less caregiver involvement, making it harder to maintain consistent medication adherence."

Lee added that the widening gap between the choline group and the placebo group at 48 weeks — compared with 24 weeks — among protocol-adherent patients was "an important signal pointing to the drug's genuine pharmacological effect and the direction future research should take."

Lee also flagged the 48-week observation period — roughly one year — as a structural limitation. "Recent global Alzheimer's drug trials, including lecanemab, run for a minimum of 18 months and as long as 36 months," he said. "Given how slowly MCI changes in its early stages, 48 weeks is simply too short to demonstrate a delay in dementia conversion."

Lee also recommended that real-world data-based long-term cohort studies be considered alongside randomized controlled trials to compensate for the inherent limitations of RCTs. A large-scale cohort study by researchers at Wonju Severance Christian Hospital analyzing 508,107 MCI patients found that choline alfoscerate users had a relatively 10.1 percent lower risk of converting to Alzheimer's dementia and a 16.8 percent lower risk of converting to vascular dementia.

"Observational studies cannot fully replace RCTs, but long-term data with rigorous control of confounding variables — through multivariate analysis or propensity score matching — are important supplementary evidence for gauging real-world clinical utility," Lee added.

'20% of patients dropping out amid restrictions with no alternative — blind faith in supplements must stop'

Lee identified the absence of treatment options as the greatest challenge in clinical practice today. With acetyl-L-carnitine and oxiracetam having been withdrawn from the market, existing dementia drugs such as donepezil are only covered by insurance once a dementia diagnosis is confirmed. The latest antibody-based new drugs are also difficult to use broadly at the MCI stage due to high costs and safety concerns.

"Since choline alfoscerate was reclassified under selective benefit coverage, the patient co-payment rate rose from 50 percent to 80 percent, and about 20 percent of existing patients are abandoning treatment because of the financial burden," Lee said. "For elderly patients, even an increase of around 20,000 won ($15) a month in out-of-pocket drug costs is a significant burden."

The concern is that patients who discontinue treatment are turning to unverified "brain nutrition" supplements and other health functional foods that can cost hundreds of thousands of won a month.

"Health supplements are ordinary food products — they are not medicines that treat disease," Lee said. "If your memory is not what it used to be, do not feel embarrassed or simply chalk it up to age. You must see a specialist, get an accurate diagnosis, and combine evidence-based drug treatment with lifestyle modification."


silverpaper@heraldcorp.com
This content was produced with the assistance of AI translation services.

MOST READ